FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new chimeric receptors, and can be applied in medicine. The invention encompasses the treatment of diseases by targeting T cells to body cells expressing a tumor antigen on the cell surface.
EFFECT: invention discloses various combined chimeric antigen receptors (see Fig. 1). T cells modified to express such chimeric antigen receptors can be used in the treatment of diseases characterized by the expression of one or more tumor antigens, in particular in cancer therapy.
9 cl, 6 dwg,1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2792042C2 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
| CHIMERIC ANTIGENIC RECEPTORS TO CD22 | 2012 |
|
RU2644243C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
